Galmed Pharmaceuticals Ltd GLMD

NAS: GLMD | ISIN: IL0011313900   4/06/2025
1,510 USD (+2,03%)
(+2,03%)   4/06/2025

13 mei 2025 · Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models · Persbericht

6 mei 2025 · Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models · Persbericht

28 april 2025 · Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation · Persbericht

17 april 2025 · Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers · Persbericht

15 april 2025 · Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor · Persbericht

10 april 2025 · Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor · Persbericht

2 april 2025 · Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 · Persbericht

20 maart 2025 · Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy · Persbericht

4 april 2024 · Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 · Persbericht

15 maart 2024 · Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis · Persbericht

26 september 2023 · Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis · Persbericht

14 juli 2023 · Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering · Persbericht

10 juli 2023 · Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC · Persbericht

1 juni 2023 · Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments · Persbericht

9 mei 2023 · Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC) · Persbericht

29 maart 2023 · Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 · Persbericht

8 februari 2023 · Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt · Persbericht

4 januari 2023 · Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol · Persbericht

14 december 2022 · Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement · Persbericht

4 augustus 2022 · Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results · Persbericht

Mijn selecties